Background Previous reports have suggested that hyperlipidemia may be associated with increased restenosis after successful coronary angioplasty. These studies have been compromised, however, by their retrospective nature, the small numbers involved, differences in the definition of restenosis, and inadequate quantitative angiographic follow-up at a prespecified time interval. The objective of the study was to examine the relation between serum cholesterol and long-term restenosis after coronary angioplasty, using quantitative angiography, at a predetermined time interval.
Methods and Results The study population comprised 2753 patients (3336 lesions) prospectively enrolled and successfully completing four major restenosis trials. Cineangiographic films were processed and analyzed at a central angiographic core laboratory with the use of an automated interpolated edgedetection technique. Serum total cholesterol was measured at trial entry and at 6 months. Hypercholesterolemia was defined as total cholesterol >7.8 mmol . L`at trial entry. Two approaches were used to assess restenosis: first, a categorical approach using the cutoff point of >50% diameter stenosis at follow-up and second, a continuous approach examining changes in minimal luminal dimensions, the absolute loss (change in minimum luminal diameter after PTCA to followup, in mm) and relative loss (absolute loss corrected for vessel size), which may give a better understanding of Conversely, the total serum cholesterol in patients with restenosis (using the categorical definition) was similar to those without restenosis (5.84± 1.24 versus 5.81± 1.22 mmol/L, respectively, P=NS). Dividing the population into deciles according to total cholesterol and examining the categorical restenosis rate (by X 2) as well as the absolute and relative loss by ANOVA again revealed no significant differences between deciles. Subgroup analysis of 579 patients (667 lesions) with HDL and LDL cholesterol levels available again revealed no differences in the categorical restenosis rate (by x 2) iarge series of patients undergoing successful balloon angioplasty and routine follow-up angiographic assessment at a predetermined time interval.
Methods Patients
The study population comprised 3582 patients with significant primary stenoses in native coronary arteries who were prospectively enrolled into four major restenosis trials.14-17 These demonstrated that active therapy had no effect on restenosis or clinical outcome in the first 6 months after balloon angioplasty, so for the purposes of this study, the data for the active and placebo groups were pooled. Patients were eligible for study entry if they were symptomatic or asymptomatic men, or women without child-bearing potential, with stable or unstable angina pectoris and proven angiographically significant narrowing in one or more major coronary arteries. Informed consent was obtained in all cases before the coronary angioplasty procedure. Patients with developing myocardial infarction and significant left main coronary artery disease were excluded from the study.
Serum Cholesterol Measurements
Serum cholesterol measurements were taken before percutaneous transluminal coronary angioplasty (PTCA) and at the time of 6-month follow-up angiography by each individual center. Sample analysis was carried out locally in all participating centers. Hypercholesterolemia was defined as a serum cholesterol level >7.8 mmol * L`1 at trial entry.'8 A cholesterol level of <7.8 mmol . L-1 was, for the purposes of this study, defined as "normal" cholesterol.
Angioplasty Procedure and Follow-up Angiography
Coronary angioplasty was performed with a steerable, movable guide wire system by the femoral route. Standard balloon catheters were used. The choice of balloon type and brand as well as inflation pressure and duration were left to the discretion of the operator. Patients were followed up for 6 months, at which time a follow-up study was performed. If symptoms recurred within 6 months, coronary angiography was carried out earlier. If no definite restenosis was present and the follow-up time was <4 months, the patient was asked to undergo further coronary arteriography at 6 months.
Quantitative Angiography
Three coronary angiograms, in total, were obtained for each patient: before PTCA, after PTCA, and at angiographic follow-up. The angiograms were recorded in such a manner that they were suitable for quantitative analysis by the computer-assisted Coronary Angiography Analysis System (CAAS). To standardize the method of data acquisition and to ensure exact reproducibility of the angiographic studies, measures were taken as previously described, and all angiograms were processed in a central angiographic core laboratory.14-'7 All cineangiograms were analyzed with the computer-assisted CAAS technique, which was described and validated earlier.13 '19 Because the computer algorithm is unable to measure total occlusions, a value of 0 mm was substituted for the minimal lumen diameter and a value of 100% for the percent diameter stenosis before PTCA. In these cases, the postangioplasty reference diameter was substituted for vessel size.
Angiographic Definitions Used
Vessel size refers to the reference diameter of the relevant coronary segment and is represented by the interpolated reference diameter before PTCA, since this is the closest and most objective approximation of the disease-free vessel wall. Minimum luminal diameter (MLD) is the point of maximal luminal narrowing in the analyzed segment.
Many criteria have been proposed for the assessment of restenosis.20 For the purposes of this study, two approaches were used: first, the categorical approach widely used by clinicians who favor the traditional cutoff point of >50% diameter stenosis at follow-up; and second, a continuous approach using absolute and relative losses, which reflect the behavior of the lesion during and after angioplasty and may be better representations of the pathological process involved during follow-up.21 '22 Absolute gain and absolute loss represent the improvement in minimal luminal diameter achieved at intervention and the absolute change during follow-up, respectively, measured in mm. Absolute gain is defined as MLD after PTCA minus MLD before PTCA. Absolute loss is MLD after PTCA minus MLD at follow-up.
Relative gain and relative loss depict the improvement in minimal luminal diameter achieved at intervention and the change during follow-up, respectively, normalized for vessel size. Relative gain is (MLD after PTCA minus MLD before 
Results

Patient Characteristics and Procedural Results
The study population comprised 2753 patients (3336 lesions, 1.21 lesions per patient) who successfully completed the study (Fig 1) . Of Tables 2 and 3. The incidence of known hyperlipidemia, as would be expected, was significantly higher in the high-cholesterol group; otherwise, the two groups were comparable in terms of known risk factors for coronary artery disease. In particular, smoking, either past or current, At the 6-month angiographic follow-up, the overall restenosis rate for the study population was 33.6% by the categorical (>50% stenosis at follow-up) approach. The MLD at follow-up was 1.44±0.59 mm for patients with and 1.44+0.58 mm for patients without hypercholesterolemia (Fig 2) . The percent stenosis at follow-up was again similar, 45.47±19.46% for patients with and 45.86±19.16% for patients without hypercholesterolemia (Fig 2) . The absolute loss was also similar for the two groups (Fig 3a) , as were the relative loss, net gain, and net gain index (Table 3) . By the criterion of >50% diameter stenosis at follow-up, there were no differences in restenosis rates between patients with and without hypercholesterolemia (31 (Table 4 ). The net gain and net gain index were also similar in all groups. Additionally, cumulative distribution curves of the top and bottom deciles for cholesterol showed no differences in either MLD at follow-up, percent stenosis at follow-up (Fig 4) , or absolute loss (Fig 3b) . Linear Regression Analysis of Total Cholesterol Linear regression analysis was used to further evaluate the relation between total cholesterol at trial entry and absolute loss (Fig 5) , as well as relative loss, net gain, and net gain index (Table 5 ). There were no significant relations between any of the measured variables and total cholesterol ( Table 5 ). The change in cholesterol level during follow-up was normally distributed around the zero mark. There was a high correlation between cholesterol level at trial entry and at the 6-month angiographic follow-up (r=.61, P<.00001). Linear regression analysis of the cholesterol level at 6 months, the mean cholesterol level, and the change in cholesterol level over this period again failed to demonstrate any relation between these and any angiographic parameters of restenosis (Table 5) .
Exclusion of Covert Influence of Trial Medication
To exclude any covert influence by the trial medication on lipid levels, subgroup analysis was performed, examining the change in cholesterol levels (mmol L`1) from trial entry to the 6-month follow-up in the separate studies. There were no significant differences between the active drug groups (A) and the placebo groups (P) in any study [CARPORT, 0.13-+±1.19 (A) Subgroup analysis was performed on 667 lesions in 579 patients in whom cholesterol subfractions were available to examine the influence of LDL cholesterol, HDL cholesterol, and LDL:HDL cholesterol ratio on restenosis during follow-up. This patient population was divided into deciles according to these cholesterol parameters, and we examined for differences between deciles for restenosis rates, absolute loss, relative loss, net gain, and net gain index (Table 6 ). There were no significant differences in any of the examined parameters between deciles or between patients in the top and bottom deciles for HDL and LDL cholesterol or LDL:HDL ratio.
Linear regression analysis was used to further evaluate the relation between LDL (Fig 6) , HDL (Fig 7) , and LDL:HDL ratio (Fig 8) and absolute loss as well as relative loss, net gain, and net gain index (Tables 7, 8 , and 9). There was a negative relation between increasing LDL levels and absolute loss (Fig 6, Table 7 ). This negative relation between increasing LDL levels and absolute as well as relative loss (Fig 6, Table 7 ) persisted even when the data were analyzed on a population basis (P=.03 and P=.02, respectively). The negative relation between increasing LDL levels and absolute loss was due solely to 29 lesions that had occluded at follow-up angiography. When these were removed from the analysis, there was no longer any significant relation between increasing LDL levels and absolute loss (P=.264). Interestingly, the mean LDL cholesterol level was signif- we27 and others28 have previously demonstrated, all lesions undergo restenosis to some extent during follow-up, in a gaussian distribution. Second, if we treat restenosis as a continuous variable, more information can be gleaned from the available data regarding the underlying process itself.22 Furthermore, we have further expanded on experimental29 and pathological evidence30 suggesting that a greater acute gain after intervention is associated with a greater loss during follow-up by introducing the concept of relative gain to represent vessel injury and relative loss to represent "intimal hyperplasia."'31 Thus, the application of quantitative angiography and the principles of absolute and relative loss provides a useful tool for the objective measurement of the degree of biological renarrowing during the weeks and months after intervention. 21, 22 The application of this to our data allows us to comment on the biological processes occurring after intervention and examine the hypothesis that hyperlipidemia influences restenosis in detail. We have shown that hypercholesterolemia is not a significant risk factor for restenosis. Furthermore, we have shown that within the angioplasty population, there is no significant relation between serum cholesterol before PTCA and at 6-month follow-up, mean cholesterol level or change in cholesterol level during follow-up, and restenosis. Subgroup analysis also demonstrated that HDL and LDL:HDL ratios have no significant influence on subsequent restenosis, although there was a negative relation between LDL cholesterol level and absolute loss. Finally, we have shown that even if we take the two extreme deciles, again there is no difference in any angiographic measure of restenosis. Thus, the assumption that total cholesterol, a risk factor for atherosclerosis, may also be a risk factor for restenosis after angioplasty has not been confirmed by this study. The negative relation between increasing LDL levels and absolute loss is interesting and was due solely to 29 lesions that had occluded at follow-up angiography. When these were removed from the analysis, there was no longer any significant relation between increasing LDL levels and absolute loss. Intriguingly, the mean LDL cholesterol level was significantly lower in lesions with than without occlusion at follow-up. This is a paradoxical finding, the reasons for which are unclear. Although LDL cholesterol is known to promote platelet aggregation32 and increases in plasma viscosity have been reported in hyperlipidemic patients,33 it is unclear why a low LDL cholesterol should increase the likelihood of occlusion at follow-up angiography. Furthermore, this goes against recent hypotheses that LDL cholesterol reduction, by depleting lipid from fatty lesions prone to rupture, stabilizes the atherosclerotic plaque. 34 
